ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1838 • 2012 ACR/ARHP Annual Meeting

    10-Year Trends in the Use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Biologic Agents in Rheumatoid Arthritis: A National Veteran Affairs Study

    Bernard Ng1, Nancy Petersen2, Hong-Jen Yu2, Myrna Khan2 and Maria E. Suarez-Almazor3, 1Dept of Rheumatology, Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, TX, 2Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, TX, 3The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX

    Background/Purpose: It is unclear how recommendations for disease modifying anti-rheumatic drugs (DMARDs) & biological agents in treatment of Rheumatoid Arthritis (RA) have influenced their use…
  • Abstract Number: 1798 • 2012 ACR/ARHP Annual Meeting

    Macrophage Migration Inhibitory Factor Regulates Dual-Specificity Phosphatases Via Glucocorticoid Induced Leucine Zipper

    Huapeng Fan, Devi Ngo, Ran Gu and Eric Morand, Medicine, Monash University, Melbourne, Australia

    Background/Purpose: Macrophage migration inhibitory factor (MIF) plays a pivotal role in promotion of inflammatory diseases such as rheumatoid arthritis (RA). MIF has previously been shown…
  • Abstract Number: 1799 • 2012 ACR/ARHP Annual Meeting

    ONO-4059 – A Novel Small Molecule Bruton’s Tyrosine Kinase (Btk) Inhibitor, Suppresses Osteoclast Differentiation and Activation

    Yuko Ariza, Toshio Yoshizawa, Yoshiko Ueda, Shingo Hotta, Masami Narita and Kazuhito Kawabata, Discovery Research Laboratories 3, Ono Pharmaceutical Co., Ltd., Osaka, Japan

    Background/Purpose:  Bruton’s tyrosine kinase (Btk) is primarily expressed in B cells, mast cells, platelets, myeloid cells and osteoclasts. Osteoclast differentiation is regulated by signaling pathways…
  • Abstract Number: 1800 • 2012 ACR/ARHP Annual Meeting

    Macrophages in Hypoxic Rheumatoid Joints Preferentially Express Hypoxia Inducible Transcription Factor-2

    Sarah Aynsley1, Ursula Fearon2, Anthony G. Wilson1 and Munitta Muthana3, 1Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, 2Rheumatology, Translation Research Group, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 3Infection and Immunity, University of sheffield, Sheffield, United Kingdom

    Background/Purpose: In rheumatoid arthritis (RA), the influx of inflammatory cells as well as the aggressive proliferation of fibroblast-like synovial cells (FLS) outstrips the oxygen supply…
  • Abstract Number: 1801 • 2012 ACR/ARHP Annual Meeting

    Biological Roles of C5orf30 in Rheumatoid Arthritis

    Munitta Muthana1, Sachin Khetan2, Gbadebo Adeleke Adeleke3, Simon Tazzyman3, Sarah Aynsley1, Fiona Morrow1, Sarah Hawtree1, Barbara Ciani4 and Anthony G. Wilson1, 1Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, 2Infection and immunity, Dr, Sheffield, United Kingdom, 3Infection and Immunity, Dr, Sheffield, United Kingdom, 4Chemistry, University of Sheffield, Sheffield, United Kingdom

    Background/Purpose: A recent genome wide association study identified the variant rs26232 in the first exon of an uncharacterized gene C5orf30. In addition, this variant is…
  • Abstract Number: 1802 • 2012 ACR/ARHP Annual Meeting

    Interleukin-29 Modulates Proinflammatory Cytokine Production in Synovial Inflammation of Rheumatoid Arthritis

    Miaojia Zhang, Fang Wang, Lingxiao Xu and Wenfeng Tan, Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China

    Background/Purpose: The immunoregulatory function of interleukin (IL)-29 has recently been recognized. However, little is known about the involvement of IL-29 in the pathogenesis of rheumatoid…
  • Abstract Number: 1803 • 2012 ACR/ARHP Annual Meeting

    Chemokine-Like Receptor 1 (CMKLR1), a G Protein Coupled Receptor Expressed On Proinflammatory Monocytes in Arthritis, Is Negatively Regulated by GRK3

    D. Stephen Serafin1, Roman Timoshchenko1, Marcus W. McGinnis2 and Teresa K. Tarrant3, 1Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Thurston Arthritis Research Center, University of North Carolina Sch of Med, Chapel Hill, NC, 3Medicine/Rheumatology, UNC School of Medicine, Chapel Hill, NC

    Background/Purpose: Chemokine-like receptor 1 (CMKLR1) is a G protein coupled receptor (GPCR) expressed by inflammatory monocytes that are pathogenic in human diseases such as psoriasis…
  • Abstract Number: 1804 • 2012 ACR/ARHP Annual Meeting

    TNF-Like Protein 1A/Death Receptor 3 Pathway Regulates Osteoclastogenesis and Is Associated with Erosive Disease in Rheumatoid Arthritis

    Fraser L. Collins1, Michael D. Stone2, Rhian Goodfellow3, Ernest Choy4, Edward C. Wang5 and Anwen S. Williams6, 1Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, 2University Hospital Llandough, Cardiff & Vale University Health Board, Cardiff, United Kingdom, 3Section of Rheumatology, Cardiff University, Cardiff, ENGLAND, United Kingdom, 4Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, 5Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, 6Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom

    Background/Purpose: Bone erosion is a characteristic feature of inflammatory arthritides, such as rheumatoid arthritis (RA). Death Receptor 3 (DR3) and its only known ligand TNF-like…
  • Abstract Number: 1805 • 2012 ACR/ARHP Annual Meeting

    The Pro-Fibrotic Cytokines IL-33 and IL-13 Modulates Dermal Fibrosis Via the A2A Adenosine Receptor

    Ross C. Radusky1, Jessica L. Feig2, Bruce N. Cronstein3, Andrew G. Franks Jr.4 and Edwin SL Chan1, 1Medicine, New York University School of Medicine, New York, NY, 2Medicine. Department of Translational Medicine, New York University School of Medicine, New York, NY, 3Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, 4Dermatology & Medicine (Rheumatology), New York University, New York, NY

    Background/Purpose: We have previously demonstrated that the nucleoside adenosine mediates collagen production and induce dermal fibrosis in in vitro and in vivo models. IL–13 expression…
  • Abstract Number: 1806 • 2012 ACR/ARHP Annual Meeting

    A Novel Angiopoetin2/TEK Tyrosine Kinase Receptor Mediated Effect On Leukocyte Cell Influx and Oxidative Damage in Inflammatory Arthritis

    Emese Balogh1, Chin T. Ng1, Douglas J. Veale2, Ursula Fearon1 and Monika Biniecka1, 1Rheumatology, Translation Research Group, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 2Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland

    Background/Purpose: The Angiopoietin2 (Ang2)/TEK Tyrosine Kinase Receptor (Tie2) signalling pathway acts synergistically with VEGF/flk as critical regulators of new vessel growth, morphology and stability possibly…
  • Abstract Number: 1808 • 2012 ACR/ARHP Annual Meeting

    Immune Activating Effects of Co-Stimulation of TLR Agonists and Cytokines On Primary and Immortalized Keratinocytes From a Patient with a CARD14 Mediated Pustular Psoriasis (CAMPS) and Healthy Controls

    Yongqing Chen1, Yin Liu2, Yan Huang1, Carole Yee3, Alison MacBride4, Anne Bowcock5, Michelle Lowes6 and Raphaela T. Goldbach-Mansky2, 1Translational Autoinflammatory Disease Section, Office of the Clinical Director NIAMS, Bethesda, MD, 2Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 3Dermatology Branch, NCI, NIH, Bethesda, MD, 4DNA Tumor Virus Section, NIAID, NIH, Bethesda, MD, 5Washington University, St. Louis, MO, 6Laboratory for Investigative Dermatology, The Rockefeller University, Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY

    Background/Purpose: Through producing inflammatory cytokines and chemokines, keratinocytes play an important role along with hematopoietic cells in mediating an inflammatory response in psoriasis and other…
  • Abstract Number: 1809 • 2012 ACR/ARHP Annual Meeting

    Serum IFNα Activity in Systemic Lupus Erythematosus Drops in Response to Immunosuppressive Therapy Only When There Is Concurrent Clinical Response

    Elzbieta E. Jacek1, Elena Gkrouzman1, Mikhail Olferiev1, Nancy Pan2, Roland Duculan3, Kyriakos A. Kirou1 and Mary K. Crow4, 1Hospital for Special Surgery, New York, NY, 2Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, 3Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, Hospital for Special Surgery, New York, NY, 4Department of Medicine, Hospital for Special Surgery, New York, NY

    Background/Purpose: The type I interferon (IFN-I) signature, describing expression in PBMC of a large set of gene transcripts induced by IFN-I, and increased serum IFNα…
  • Abstract Number: 1810 • 2012 ACR/ARHP Annual Meeting

    Identification and Characterization of Synthetic Small Molecule Macrocycle Antagonists of Human IL17A

    David Livingston, Sethu Alexander, Julian Bond, Timothy Briggs, Andrew Fraley, Stephen Hale, Tanya Landsman, Richard Martinelli, Kelley Shortsleeves, Nick Terrett and Nathan Walsh, Ensemble Therapeutics, Cambridge, MA

    Background/Purpose: :  IL17A has been demonstrated to be a key pro-inflammatory cytokine in human rheumatoid arthritis and in several rodent models of arthritis.  Synthetic macrocycles…
  • Abstract Number: 1811 • 2012 ACR/ARHP Annual Meeting

    On the Origin of the Type I Interferon Signature in Rheumatoid Arthritis

    T.D. de Jong1, Saskia Vosslamber1, Maija-Leena Eloranta2, Lars Rönnblom2, Kyra Gelderman1, Mary von Blomberg1, Irene Bultink3, Alexandre Voskuyl4 and Cornelis L. Verweij1, 1Pathology, VU University Medical Center, Amsterdam, Netherlands, 2Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 3Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 4Rheumatology, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Presence of a type I interferon (IFN) signature has been described for several autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).…
  • Abstract Number: 1812 • 2012 ACR/ARHP Annual Meeting

    A Retrospective Evaluation of the Clinical and Economic Implications of Gout in Nursing Home Residents in Hawaii Treated with Allopurinol

    Joy Higa1, Gregory Reardon2 and Gregory Tong3, 1Long Term Care Research Center, Kaneohe, HI, 2Informagenics, LLC, Worthington, OH, 3Takeda Pharmaceuticals America, Inc., Deerfield, IL

    Background/Purpose: We describe patient characteristics, serum uric acid (sUA) levels while on allopurinol, and activities of daily living (ADL) in nursing home residents with gout.…
  • « Previous Page
  • 1
  • …
  • 2299
  • 2300
  • 2301
  • 2302
  • 2303
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology